Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Duricova

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|November 20, 2015
Review article: the natural history of paediatric-onset ulcerative colitis in population-based studiesM Fumery, D Duricova, C Gower-Rousseau, et al.
Digestive Diseases (Basel, Switzerland)|February 2, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases CentreM Kolar, D Duricova, M Bortlik, et al.
Journal of Crohn'S & Colitis|January 7, 2020
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical CentreMartin Lukas, K Malickova, M Kolar, et al.
Scandinavian Journal of Gastroenterology|March 2, 2022
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohortsM Lukas, M Kolar, J Reissigova, et al.
Alimentary Pharmacology & Therapeutics|September 14, 2012
eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s diseaseN Pedersen, M Elkjaer, D Duricova, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Infliximab dependency in children with Crohn's diseaseD Duricova, N Pedersen, M Lenicek, et al.
Alimentary Pharmacology & Therapeutics|August 6, 2011
Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006A Bortoli, N Pedersen, D Duricova, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2013
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant womenN Pedersen, A Bortoli, D Duricova, et al.
Journal of Crohn'S & Colitis|June 10, 2015
Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception CohortZ Vegh, J Burisch, N Pedersen, et al.
Journal of Crohn'S & Colitis|July 8, 2014
Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohortZ Vegh, J Burisch, N Pedersen, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|November 20, 2015
Review article: the natural history of paediatric-onset ulcerative colitis in population-based studiesM Fumery, D Duricova, C Gower-Rousseau, et al.
Digestive Diseases (Basel, Switzerland)|February 2, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases CentreM Kolar, D Duricova, M Bortlik, et al.
Journal of Crohn'S & Colitis|January 7, 2020
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical CentreMartin Lukas, K Malickova, M Kolar, et al.
Scandinavian Journal of Gastroenterology|March 2, 2022
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohortsM Lukas, M Kolar, J Reissigova, et al.
Alimentary Pharmacology & Therapeutics|September 14, 2012
eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s diseaseN Pedersen, M Elkjaer, D Duricova, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Infliximab dependency in children with Crohn's diseaseD Duricova, N Pedersen, M Lenicek, et al.
Alimentary Pharmacology & Therapeutics|August 6, 2011
Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006A Bortoli, N Pedersen, D Duricova, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2013
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant womenN Pedersen, A Bortoli, D Duricova, et al.
Journal of Crohn'S & Colitis|June 10, 2015
Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception CohortZ Vegh, J Burisch, N Pedersen, et al.
Journal of Crohn'S & Colitis|July 8, 2014
Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohortZ Vegh, J Burisch, N Pedersen, et al.
Pageof 2